Breast Cancer Canada is reporting live from ESMO Congress in Berlin, connecting with Canadian and global researchers, oncologists, and innovators who are shaping the next era of precision breast cancer care.

From early detection to metastatic treatment advances, the conversation is clear: personalized treatment isn’t the future: it’s right now.

We’re here for Canadian patients. We’re here to bring home progress.

Natalee Trial / Kisqali Update

Breaking news from #ESMO25
The NATALEE breast cancer trial results are in, marking a major advancement with Kisqali (ribociclib) in early-stage HR+/HER2- breast cancer.

What this means:
 A targeted therapy traditionally used in metastatic disease is now proving benefit earlier in the treatment journey.
 Reduce the risk of the breast cancer returning (recurrence)
 Patients have more treatment options.

We’re following this closely and speaking with Canada’s leading oncologists on what this means for access and clinical adoption at home.

Science leads. Progress follows.

MonarchE Study

ESMO sessions are reinforcing the growing global consensus: CDK4/6 inhibitors are redefining early breast cancer treatment standards.

The MONARCH(e) study continues to show that adding targeted CDK4/6 inhibition therapy can reduce risk of recurrence for patients with node-positive, high-risk HR+/HER2- breast cancer.

The takeaway: treatment is becoming more tailored, more strategic, and more aligned with individual risk.

We’re here to ask the Canadian question:
 How soon can this research reach more patients across Canada? 

 

ASCENT-03 Trial with Trodelvy in Frontline Treatment for Metastatic TNBC: Expanding the Window for Precision Treatment

Today at ESMO in Berlin, new data introduced a shift in how metastatic triple-negative breast cancer (TNBC) could be treated.

Trodelvy® (sacituzumab govitecan), originally used later in the course of metastatic disease, has now been evaluated as initial treatment when metastatic TNBC is first known.

Why this marks a change in direction:

• TNBC is biologically aggressive and has lacked novel chemotherapy options.

• Using Trodelvy earlier in metastatic TNBC is showing evidence prolonging cancer control (progression-free survival).

• Trodelvy has now been evaluated in 3 large clinical trials all with improvement in survival outcomes for metastatic TNBC

Breast Cancer Canada is advocating for these innovations to reach Canadian patients without delay. Stay tuned to Know More on research results, future regulatory approvals and access.

 

Results from the DESTINY-Breast05 trial for Enhertu signal a turning point for patients with HER2-positive early breast cancer with a high risk of returning. The research results show 92% of patients remained in remission at three years after receiving the drug treatment Enhertu.

This shift underscores the impact of targeted drugs designed with precision. Enhertu exemplifies how antibody-drug conjugates can change the trajectory of early-stage disease beyond its use in metastatic settings.

Breast Cancer Canada is closely aligned with these developments, advocating for science-led treatment pathways to be reflected in Canadian care systems — with equity and speed at the forefront.

TROPION BREAST -02 Dato-DXd Trial: Expanding ADC Options in Advanced Breast Cancer

From the #ESMO25 updates: Datopotamab Deruxtecan (Dato-DXd) is showing meaningful activity in metastatic triple-negative breast cancer (mTNBC) who are not eligible for immunotherapy and starting initial treatment for advanced cancer.
Key signals from the data:

• Evidence presented showed improvements in longer disease control and survival outcomes

• This reinforces the momentum of precision chemotherapy treatment, especially in an aggressive form of breast cancer like mTNBC.

Breast Cancer Canada continues to champion rapid adoption of novel therapies in Canada — because innovation is only meaningful when it’s accessible.